There is some evidence indicating that hydroxychloroquine may have anti-cytokine shock properties. Tocilizumab was included in treatment guidelines by the Chinese National Health Commission after a small study was conducted.
Kuna ushahidi kwamba dawa ya hydroxychloroquine inaweza kuwa na sifa za kupambana na ongezeko kupita kiasi la sitokini. Tocilizumab imejumuishwa kwenye maelekezo ya matibabu ya Tume ya Afya ya kitaifa ya China baada ya utafiti mdogo kukamilishwa.